Cargando…
843. The PALM Consortium: A Multicenter, Multioutbreak Randomized Controlled Trial of Ebola Virus Disease Therapeutics
BACKGROUND: Recent outbreaks of Ebola virus disease in the Democratic Republic of the Congo (DRC) reinforce the desperate need to establish definitively the comparative safety and efficacy of different medical countermeasures (MCM). METHODS: Through a multipartner governance framework under WHO coor...
Autor principal: | Mulangu, Sabue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809330/ http://dx.doi.org/10.1093/ofid/ofz359.028 |
Ejemplares similares
-
Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection
por: Tshiani Mbaya, Olivier, et al.
Publicado: (2021) -
843. Targeted HIV Testing for Patients Hospitalized for COVID-19
por: Virata, Michael D, et al.
Publicado: (2021) -
High prevalence of IgG antibodies to Ebola virus in the Efé pygmy population in the Watsa region, Democratic Republic of the Congo
por: Mulangu, Sabue, et al.
Publicado: (2016) -
Development of Ebola virus disease prediction scores: Screening tools for Ebola suspects at the triage-point during an outbreak
por: Tshomba, Antoine Oloma, et al.
Publicado: (2022) -
843. Increased Carbapenemase Testing Following Implementation of VA Guidelines for Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Fitzpatrick, Margaret A, et al.
Publicado: (2020)